{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:57:14Z","timestamp":1792202234067,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.radonc.2024.110517","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T16:27:27Z","timestamp":1725035247000},"page":"110517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-5435","authenticated-orcid":false,"given":"Yang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangjie","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-0875","authenticated-orcid":false,"given":"Guangxian","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongling","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0583-240X","authenticated-orcid":false,"given":"Dong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110517_b0005","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2024.110517_b0010","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","volume":"36","author":"Yang","year":"2018","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110517_b0015","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","article-title":"Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.radonc.2024.110517_b0020","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"van der Gaast, Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110517_b0025","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/SLA.0000000000006018","article-title":"Neoadjuvant Chemoradiotherapy Versus Chemotherapy for the Treatment of Locally Advanced Esophageal Adenocarcinoma in the European Multicenter ENSURE Study","volume":"278","author":"Elliott","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2024.110517_b0030","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"The Lancet Gastroenterology hepatology"},{"key":"10.1016\/j.radonc.2024.110517_b0035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial","volume":"34","author":"Tang","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2024.110517_b0040","first-page":"660","article-title":"A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction, Annals of oncology : official journal of the European Society for","volume":"27","author":"Klevebro","year":"2016","journal-title":"Med Oncol"},{"key":"10.1016\/j.radonc.2024.110517_b0045","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1200\/JCO.22.02279","article-title":"Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma","volume":"41","author":"Faron","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110517_b0050","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/gut.2003.025080","article-title":"Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis","volume":"53","author":"Fiorica","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.radonc.2024.110517_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101183","article-title":"Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis","volume":"42","author":"Fan","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.radonc.2024.110517_b0060","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1111\/1759-7714.14588","article-title":"Comparison of different neoadjuvant treatments for resectable locoregional esophageal cancer: A systematic review and network meta-analysis","volume":"13","author":"Bao","year":"2022","journal-title":"Thoracic cancer"},{"key":"10.1016\/j.radonc.2024.110517_b0065","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.tps4152","article-title":"Next study (JCOG1109): A three-arm randomized phase III study comparing preoperative CDDP+5-FU(CF) versus docetaxel+CF versus CF-radiation followed by esophagectomy with D2\u20133 lymphadenectomy for locally advanced esophageal squamous cell cancer","volume":"31","author":"Kato","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110517_b0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.radonc.2024.110517_b0075","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement","volume":"313","author":"Stewart","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2024.110517_b0080","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2024.110517_b0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.radonc.2024.110517_b0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.radonc.2024.110517_b0095","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1442-2050.2008.00910.x","article-title":"Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma, Diseases of the esophagus : official journal of the International Society for","volume":"22","author":"Cao","year":"2009","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.radonc.2024.110517_b0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.radonc.2024.110517_b0105","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/BF02067069","article-title":"Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer","volume":"16","author":"Nygaard","year":"1992","journal-title":"World J Surg"},{"key":"10.1016\/j.radonc.2024.110517_b0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","article-title":"Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial","volume":"404","author":"Kato","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.radonc.2024.110517_b0115","doi-asserted-by":"crossref","first-page":"675","DOI":"10.4103\/jcrt.jcrt_940_21","article-title":"To compare neoadjuvant concurrent chemo-radiotherapy followed by surgery and neoadjuvant chemotherapy followed by surgery in carcinoma esophagus patients: A single institutional study in the Indian population","volume":"19","author":"Purkayastha","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.radonc.2024.110517_b0120","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.18.02122","article-title":"Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial","volume":"37","author":"Chen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110517_b0125","doi-asserted-by":"crossref","first-page":"e220120","DOI":"10.1001\/jamanetworkopen.2022.0120","article-title":"Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial","volume":"5","author":"Ai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.radonc.2024.110517_b0130","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.23.02009","article-title":"Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial","volume":"42","author":"Jia","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110517_b0135","first-page":"1568","volume":"13","author":"Tebbutt","year":"2002","journal-title":"Med Oncol"},{"key":"10.1016\/j.radonc.2024.110517_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100422","article-title":"Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study)","volume":"24","author":"Zhou","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.radonc.2024.110517_b0145","first-page":"681","article-title":"Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis, The Lancet","volume":"12","author":"Sjoquist","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.radonc.2024.110517_b0150","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1470-2045(07)70039-6","article-title":"Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis","volume":"8","author":"Gebski","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2024.110517_b0155","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12032-023-02097-4","article-title":"Current neoadjuvant therapy for operable locally advanced esophageal cancer","volume":"40","author":"Yang","year":"2023","journal-title":"Medical oncology (Northwood, London, England)"},{"key":"10.1016\/j.radonc.2024.110517_b0160","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.apsb.2021.09.028","article-title":"Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy","volume":"12","author":"Zhang","year":"2022","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.radonc.2024.110517_b0165","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41571-023-00757-y","article-title":"Improving outcomes in patients with oesophageal cancer","volume":"20","author":"Shah","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110517_b0170","first-page":"113","article-title":"Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010, European journal of cancer (Oxford","volume":"138","author":"Liu","year":"1990","journal-title":"England"},{"key":"10.1016\/j.radonc.2024.110517_b0175","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/14737140.2022.2110470","article-title":"Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review","volume":"22","author":"Xu","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.radonc.2024.110517_b0180","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/SLA.0000000000004930","article-title":"Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: A Systematic Review and Individual Patient Data Meta-analysis","volume":"275","author":"van der Wilk","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2024.110517_b0185","first-page":"965","article-title":"Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study, The Lancet","volume":"19","author":"Noordman","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.radonc.2024.110517_b0190","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2024.110517_b0195","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","author":"Qin","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.radonc.2024.110517_b0200","doi-asserted-by":"crossref","first-page":"1108213","DOI":"10.3389\/fimmu.2023.1108213","article-title":"Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis","volume":"14","author":"Qin","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.radonc.2024.110517_b0205","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41416-023-02286-y","article-title":"Chemoradiotherapy versus triplet chemotherapy as initial therapy for T4b esophageal cancer: survival results from a multicenter randomized Phase 2 trial","volume":"129","author":"Yamasaki","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2024.110517_b0210","first-page":"824","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial, The Lancet","volume":"22","author":"Altorki","year":"2021","journal-title":"Oncology"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024034959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024034959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T16:25:50Z","timestamp":1750695950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024034959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":42,"alternative-id":["S0167814024034959"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110517","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110517"}}